Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial
Hongnan Mo(Chinese Academy of Medical Sciences & Peking Union Medical College), Yongpei Yu(Peking University), Xiaoying Sun(Cancer Hospital of Huanxing Chaoyang District Beijing), Hewei Ge(Chinese Academy of Medical Sciences & Peking Union Medical College), Lanlan Yu(Peking University), Xiuwen Guan(Chinese Academy of Medical Sciences & Peking Union Medical College), Jingtong Zhai(Chinese Academy of Medical Sciences & Peking Union Medical College), Aihua Zhu(Cancer Hospital of Huanxing Chaoyang District Beijing), Yuhan Wei(Chinese Academy of Medical Sciences & Peking Union Medical College), Jinjing Wang(Cancer Hospital of Huanxing Chaoyang District Beijing), Xiaoyan Yan(Peking University), Haili Qian(Chinese Academy of Medical Sciences & Peking Union Medical College), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 31
Abstract
Related Papers
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang, Jian‐Ping Yuan, Elda Righi et al.|Proceedings of the National Academy of Sciences|2012|1.1k